title: Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
abstract: Edoxaban is an oral once-daily factor Xa inhibitor with a predictable anticoagulant effect. After oral administration, edoxaban is rapidly absorbed from the gastrointestinal tract, reaching the peak plasma concentrations at 1-2 h. Oral bioavailability is 62% in healthy subjects and the terminal half-life is approximately 10-14 h. Edoxaban has been extensively studied in three clinical scenarios. In ENGAGE AF-TIMI 48, edoxaban was at least as effective as warfarin, but with a marked lesser risk of bleeding. In the Hokusai-VTE study, edoxaban was as effective as warfarin for the prevention of recurrent venous thromboembolism (VTE) in patients with deep venous thrombosis, pulmonary embolism, or both, but with a lesser risk of bleeding. In the STARS program, edoxaban was more effective for the prevention of VTE after knee or hip arthroplasty than low-dose enoxaparin, without an increased bleeding risk. In this review, the available clinical evidence about edoxaban is updated.
authors.affiliation: Department of Cardiology, University Hospital Ramon y Cajal, Alcala University, Madrid, Spain.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.forename: Carlos
authors.initials: C
authors.lastname: Escobar
mesh_terms: D000284:Administration, Oral; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications; D002986:Clinical Trials as Topic; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013844:Thiazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*
chemical_list: D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; C552171:edoxaban
keywords: ENGAGE AF-TIMI 48; Hokusai-VTE; STARS program; deep venous thrombosis; direct oral anticoagulants; edoxaban; hip arthroplasty; knee arthroplasty; new oral anticoagulants; non-valvular atrial fibrillation; pulmonary embolism; venous thromboembolism